Tuesday 30 May 2017

---

MSD has announced that it will create 330 new jobs and invest €280 million over the next three years at two of its Irish manufacturing sites. The new jobs will be created in Carlow and Cork, and the investment will see both sites expand production facilities and capacity to meet that demand. MSD currently employs over 1,600 people across four sites in Ireland – in Carlow, Cork, Dublin and Tipperary. Its Irish operations, encompassing manufacturing, commercial, global financial services and marketing facilities, had a turnover of €4.7 billion in 2016. MSD provides healthcare solutions and innovative medicines in areas such as diabetes, heart disease, immuno-oncology, infectious diseases and vaccines. MSD in Brinny, Co Cork is an integrated site for the development, testing and manufacturing of biologics, specialising in the fermentation, purification and sterile filling of biotech products. More than 200 new hires will be needed to meet demand for its work on some of the company's important treatments – medicines for lung cancer, melanoma, hepatitis C and rheumatoid arthritis. MSD in Carlow, where 120 of the new roles will be located, is the company’s first stand-alone vaccine and biologics facility outside the US. Carlow also is an important link in MSD’s network of sites producing its new immuno-oncology treatment for the global market. Available roles at the sites include technical, engineering, biochemistry, biology, quality and operations positions. The announcement was welcomed by the Minster for Jobs, Enterprise & Innovation, Mary Mitchell O’Connor on 30 May, when she addressed over 1,200 senior MSD business leaders from 50 countries, gathered in Dublin for MSD’s annual EMEAC (Europe, Middle East, Africa & Canada) Congress.